You are here

Regeneron

Just a few days after a stumble, FDA OKs 12-week dose for Eylea as Regeneron braces for Novartis attack

Just a few days after a stumble, FDA OKs 12-week dose for Eylea as Regeneron braces for Novartis attack

Endpoints

wet age-related macular degeneration

Flag link:

Teva and Regeneron's Fasinumab Meets Primary and Secondary Endpoints in Patients with Chronic Pain from Osteoarthritis of the Knee or Hip

Teva and Regeneron's Fasinumab Meets Primary and Secondary Endpoints in Patients with Chronic Pain from Osteoarthritis of the Knee or Hip

CP Wire

Teva Pharmaceutical

Flag link:

Teva and Regeneron's Fasinumab Meets Primary and Secondary Endpoints in Patients with Chronic Pain from Osteoarthritis of the Knee or Hip

Teva Pharmaceutical

Flag link:

Racing Novartis on Eylea rival, the FDA trips up Regeneron at the finish line

Racing Novartis on Eylea rival, the FDA trips up Regeneron at the finish line

Endpoints

wet age-related macular degeneration

Flag link:

Citing appeals court 'anarchy,' Amgen asks SCOTUS to weigh its PCSK9 patent spat with Sanofi

Citing appeals court 'anarchy,' Amgen asks SCOTUS to weigh its PCSK9 patent spat with Sanofi

Fierce Pharma

PCSK9 inhibitors

Flag link:

Regeneron And Bluebird Team To Invent New Cell Therapies For Cancer

Regeneron And Bluebird Team To Invent New Cell Therapies For Cancer

Forbes

Flag link:

The Week Ahead In Biotech: Conferences, PDUFA Dates And IPOs

The Week Ahead In Biotech: Conferences, PDUFA Dates And IPOs

Yahoo/Benzinga

Pain Therapeutics

Vertex Pharmaceuticals

lumacaftor/ivacaftor

Flag link:

Regeneron plots DTC advertising and discount push to put Eylea back on track

Regeneron plots DTC advertising and discount push to put Eylea back on track

Fierce Pharma

DTC advertising

Flag link:

Regeneron’s Billionaire Founder Battles The Drug Pricing System

Regeneron’s Billionaire Founder Battles The Drug Pricing System

Forbes

Leonard Schleifer

Flag link:

Allergan’s eye contender cannot knock Eylea off its perch

Allergan’s eye contender cannot knock Eylea off its perch

EP Vantage

wet age-related macular degeneration

Flag link:

Regeneron, Sanofi show restraint on Dupixent price hike, but Pfizer’s hard charge continues to spur calls for a radical change-up

Regeneron, Sanofi show restraint on Dupixent price hike, but Pfizer’s hard charge continues to spur calls for a radical change-up

Endpoints

Flag link:

Regeneron Focuses on Expanding Eylea’s Diabetic Retinopathy Label

Regeneron Focuses on Expanding Eylea’s Diabetic Retinopathy Label

Market Realist

diabetic retinopathy

Flag link:

With $460B in borrowing capacity, will any of the Big-20 biopharmas go after one of the top-5 takeover targets?

With $460B in borrowing capacity, will any of the Big-20 biopharmas go after one of the top-5 takeover targets?

Endpoints

Gilead Sciences

Flag link:

Biopharma M&A: You Ain’t Seen Nothing Yet

Biopharma M&A: You Ain’t Seen Nothing Yet

Barron's

Gilead Sciences

Flag link:

5 takeaways from the first look at cancer's biggest conference

5 takeaways from the first look at cancer's biggest conference

Biopharma Dive

Bristol-Myers Squibb

Jounce Therapeutics

Flag link:

Are These Disappointing Drugs Back on Track to Billions?

Are These Disappointing Drugs Back on Track to Billions?

Motley Fool

PCSK9 inhibitors

Flag link:

3 Reasons Regeneron Stock Could Start Climbing Again

3 Reasons Regeneron Stock Could Start Climbing Again

Yahoo/Motley Fool

Flag link:

Regeneron halts high doses of phase 3 osteoarthritis drug fasinumab amid risk-benefit concerns

Regeneron halts high doses of phase 3 osteoarthritis drug fasinumab amid risk-benefit concerns

Fierce Biotech

clinical trials

Flag link:

Regeneron (REGN) Q1 Earnings Top, Sales Lag, Updates View

Regeneron (REGN) Q1 Earnings Top, Sales Lag, Updates View

Yahoo/Zacks.com

Flag link:

Express Scripts Picks Regeneron Over Amgen, Cuts Heart Drug Price

Express Scripts Picks Regeneron Over Amgen, Cuts Heart Drug Price

Xconomy

Express Scripts

Flag link:

Pages